Regulus Therapeutics Inc., a biopharmaceutical company founded by Alnylam Pharmaceuticals (ALNY: Quote) and Isis Pharmaceuticals (ISIS: Quote), announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission relating to a proposed initial public offering of shares of its common stock. All shares of the common stock to be sold in the offering will be offered by Regulus.
Regulus noted that the number of shares to be offered and the price range for the offering have not yet been determined.
Click here to receive FREE breaking news email alerts for Alnylam Pharmaceuticals Inc. and others in your portfolio
by RTT Staff Writer
For comments and feedback: firstname.lastname@example.org